ImmunoCellular Therapeutics (IMUC) 8-K ImmunoCellular Therapeutics Announces First Quarter 2013 Financial Results

Condensed Balance Sheets
		3/31/2013		12/31/2012
		(unaudited)
Cash	$	24,104,258	$	26,216,668
Other current assets		818,042		714,508
Non current assets		148,364		88,025
	$	25,070,664	$	27,019,201
Current liabilities	$	1,157,888	$	1,098,307
Warrant liabilities		5,484,562		2,852,880
Shareholders' equity		18,428,214		23,068,014
	$	25,070,664	$	27,019,201
Condensed Statements of Operations (unaudited)
		Three months		Three months
		ended		ended
		3/31/2013		3/31/2012
Revenue		$0		$0
Research and development		1,415,261		1,998,536
Stock based compensation		164,128		245,107
General and administrative		769,267		805,798
Loss before other expenses		(2,348,656)		(3,049,441)
Interest income		6,548		1,034
Financing expense		-		(368,524)
Change in fair value of warrant liabilities		(2,631,683)		(4,472,504)
Net loss	$	(4,973,791)	$	(7,889,435)
Net loss per share, basic and diluted:	$	(0.10)	$	(0.21)